New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT05262491
Summary
This is a first-in-human study to test the safety and find the right dose of a new drug called BL-B01D1. It is for adults with advanced gastrointestinal or other solid tumors that have stopped responding to standard treatments. The main goals are to see how much of the drug the body can handle, identify side effects, and get an early look at whether it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100037, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Jinan Central Hospital
RECRUITINGJinan, Shandong, China
Contact
Contact
Contact
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, China
Contact
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact
Conditions
Explore the condition pages connected to this study.